Pluri Secures Patent for Immune Cell Expansion Technology

• Pluri Inc. has been granted a U.S. patent for a novel method for the expansion of immune cells using proprietary technology.

• The patented technology addresses the critical challenges faced by current allogeneic cell therapies, such as limited donor cell availability and scalability issues.

Biotechnology company Pluri Inc. has been granted a new U.S. patent. The CEO and President of Pluri, Yaky Yanay, believes that their continued investment in technology, paired with two decades of expertise, enables them to develop the next generation of medical treatments.

The patent is for a novel method for the expansion of immune cells using Pluri’s proprietary technology. This technology mimics the natural lymph node-like environment that immune cells have within the human body. The tightly controlled and fully automated bioreactor system provides cells with the conditions they need to expand, enabling efficient expansion of immune cells at scale and quality.

The exact date of the patent grant is not specified in the press release. The press release does not specify where the patent was granted, but it is a U.S. patent.

The patented technology addresses the critical challenges faced by current allogeneic cell therapies, such as limited donor cell availability and scalability issues. It offers a promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases.

Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node-like environment that immune cells have within the human body. The produced immune cells retain their integrity, functionality, and therapeutic efficacy. As Yanay states, “Pluri’s patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies. By harnessing the power of our proprietary technology, we are not only advancing the possibilities of allogeneic cell therapy, we are also reaffirming our commitment to improving patient outcomes worldwide.”